Author: Maclintosh Kuhlengisa
123jump.com
Last Update: 10:25 AM EST March 03 2008
The pharmaceutical company reported a 4% increase in revenues to $13.1 billion, compared with $12.6 billion the year ago quarter, despite Norvasc loss of U.S. exclusivity, which contributed to a $666 million decrease in Norvasc revenues. The firm has significantly streamlined the organization, reducing layers and increasing spans of control. It also entered into several alliances to develop new drugs.
Sources: Data collected by 123jump.com and Ticker.com from company press releases, filings and corporate websites.
Market data: BATS Exchange. Inc.
350 Fund Managers Interviews - 10-year Annual earnings on 4,600 U.S. companies - 20-quarter Earnings on 3,800 U.S. companies - 3,200 U.S. IPO Prospectuses
- 2,100 Economic data releases from U.S., EU, UK, India, HK and Australia. 10-year Annual reports on 3,500 U.S. companies -
U.S. Earnings Calendar with 4,800 companies - 90,000 10-K reports - 26,000 Global markets news archive - 2,200 Earnings Conference Call Summaries
